Insights

Innovative Therapies Akari Therapeutics is developing advanced therapies for autoimmune and inflammatory diseases, positioning them as a key player in the biotechnology research industry with high market potential for innovative treatments.

FDA Recognized Akari's lead asset, nomacopan, has received significant FDA designations like Orphan Drug and Fast Track, indicating strong potential for accelerated approval processes and increased market access.

Expanding Clinical Trials With a Phase 3 clinical trial program ongoing for pediatric hematopoietic stem cell transplant-related conditions, Akari presents partnership opportunities for institutions specializing in pediatric healthcare or stem cell research.

European Market Entry Having received orphan drug designation from the European Commission, Akari is well-positioned for market expansion in Europe, offering potential collaborations with distributors and healthcare providers across the region.

Market Gap Addressed Akari's research on long-acting PAS-nomacopan for geographic atrophy addresses an unmet need in the market, opening doors for partnerships with organizations focused on age-related degenerative diseases.

Similar companies to Akari Therapeutics, Plc

Akari Therapeutics, Plc Tech Stack

Akari Therapeutics, Plc uses 8 technology products and services including W3 Total Cache, Sucuri, WordPress, and more. Explore Akari Therapeutics, Plc's tech stack below.

  • W3 Total Cache
    Caching
  • Sucuri
    Content Delivery Network
  • WordPress
    Content Management System
  • Drupal
    Content Management System
  • Ionicons
    Font Scripts
  • Open Graph
    Miscellaneous
  • Lua
    Programming Languages
  • Adobe Tag Manager
    Tag Management

Media & News

Akari Therapeutics, Plc's Email Address Formats

Akari Therapeutics, Plc uses at least 1 format(s):
Akari Therapeutics, Plc Email FormatsExamplePercentage
First.Last@akaritx.comJohn.Doe@akaritx.com
87%
First@akaritx.comJohn@akaritx.com
5%
Last@akaritx.comDoe@akaritx.com
4%
LastF@akaritx.comDoeJ@akaritx.com
4%

Frequently Asked Questions

Where is Akari Therapeutics, Plc's headquarters located?

Minus sign iconPlus sign icon
Akari Therapeutics, Plc's main headquarters is located at 75-76 Wimpole Street London, W1G 9RT GB. The company has employees across 2 continents, including EuropeNorth America.

What is Akari Therapeutics, Plc's stock symbol?

Minus sign iconPlus sign icon
Akari Therapeutics, Plc is a publicly traded company; the company's stock symbol is AKTX.

What is Akari Therapeutics, Plc's official website and social media links?

Minus sign iconPlus sign icon
Akari Therapeutics, Plc's official website is akaritx.com and has social profiles on LinkedIn.

How much revenue does Akari Therapeutics, Plc generate?

Minus sign iconPlus sign icon
As of October 2024, Akari Therapeutics, Plc's annual revenue reached $3.8M.

What is Akari Therapeutics, Plc's SIC code NAICS code?

Minus sign iconPlus sign icon
Akari Therapeutics, Plc's SIC code is 2834 - Pharmaceutical Preparations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Akari Therapeutics, Plc have currently?

Minus sign iconPlus sign icon
As of October 2024, Akari Therapeutics, Plc has approximately 15 employees across 2 continents, including EuropeNorth America. Key team members include Chief Executive Officer: C. R.Chief Operating Officer: M. B.Head Of Cmc: M. S.. Explore Akari Therapeutics, Plc's employee directory with LeadIQ.

What industry does Akari Therapeutics, Plc belong to?

Minus sign iconPlus sign icon
Akari Therapeutics, Plc operates in the Biotechnology Research industry.

What technology does Akari Therapeutics, Plc use?

Minus sign iconPlus sign icon
Akari Therapeutics, Plc's tech stack includes W3 Total CacheSucuriWordPressDrupalIoniconsOpen GraphLuaAdobe Tag Manager.

What is Akari Therapeutics, Plc's email format?

Minus sign iconPlus sign icon
Akari Therapeutics, Plc's email format typically follows the pattern of . Find more Akari Therapeutics, Plc email formats with LeadIQ.

When was Akari Therapeutics, Plc founded?

Minus sign iconPlus sign icon
Akari Therapeutics, Plc was founded in 2015.
Akari Therapeutics, Plc

Akari Therapeutics, Plc

Biotechnology ResearchLondon, United Kingdom11-50 Employees

Akari Therapeutics, Plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA and orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation. Akari’s pipeline also includes a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA).

Section iconCompany Overview

Headquarters
75-76 Wimpole Street London, W1G 9RT GB
SIC Code
2834 - Pharmaceutical Preparations
Stock Symbol
AKTX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $10M

    Akari Therapeutics, Plc's revenue is in the range of $10M

Section iconFunding & Financials

  • $10M

    Akari Therapeutics, Plc's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.